ABOUT US
Boards of Directors and Founders
CEO and President of the Board
Chief Scientific Officer, Founder
Founder and Advisor
Director, Pharma Expert
Director, Advisor
Director, Advisor
Ricardo Perdigao Henriques, PhD.
Director
CURRICULUM
Dr. Infante obtained his Ph.D. (Microbiology and Biochemistry) from the University of Cádiz, Spain and completed his academic formation with a senior researcher position in the Department of Biochemistry of the University of Washington in Seattle, USA. He joined the biotech private sector in 2007, serving as Chief Scientific Officer of Bionaturis and ADL Bionatur Solutions in Spain. Specialized in the development of biotechnological assets, covering intellectual property, R&D, and licensing, he became CEO of Vaxdyn in November 2013.
MDDr. McConnell is a medical doctor from the University of Michigan, biochemistry graduate from the University of Notre Dame, and Ph.D. in microbiology and Immunology from the University of Michigan. He founded Vaxdyn in 2011 while researching on vaccines and immunotherapies against antibiotic-resistant bacteria at the Institute of Biomedicine of Seville. Since 2018, Dr. McConnell is a principal investigator at the Unit of Nosocomial Infections at the Microbiology National Center (CNM) of the Institutes of Health Carlos III of Spain in Madrid. He has led more than 20 research projects in bacteriology, published more than 50 articles in peer-reviewed international journals and filed 7 patents.
Dr. Pérez-Romero obtained her B.S. degree in Biology and her Ph.D. in Microbiology from the University of Seville in Spain. Currently, she is a principal investigator of Virology at the Microbiology National Center (CNM) of the Institutes of Health Carlos III of Spain in Madrid. Her work focuses on the characterization of viral infections and their immune response. She is a member of the Spanish Network for AIDS Investigation, the European Society for Clinical Microbiology and Infectious Diseases and the American Society for Virology. She was a founder of Vaxdyn while leading research in the Infectious Diseases Group at the Institute of Biomedicine of Seville.patents.
Dr. León provides the Vaxdyn’s Board of Directors with experience in biotech governance and with pharmaceutical development expertise.
Chief Scientific Officer of Provention Bio. Formerly CEO and CMO of Celimmune, VP/Head of Immunology Translational Medicine at Janssen-Johnson & Johnson, CMO of Alba Therapeutics, Director at Bristol-Myers Squibb and at MedImmune. Co-Founder of the US-based companies Celimmune (acquired by Amgen in 2017), Glutenostics (commercializes gluten-detection tests) and Provention Bio (NASDAQ: PRVB).
CEO of Genetrix group since 2010, moving to Sygnis AG after the merger done between Xpol, Genetrix subsidiary, and Sygnis Pharma AG in October 2012. During this time she closed successfully 4 capital increases within the Frankfurt stock exchange and two acquisitions, and the company developed a complete portfolio of innovative DNA reagents products. CEO of ADL Biopharma between 2017 and 2020. Since 2020, she is the general manager of Arquimea Medical, the medical division of the Madrid-based industrial group Arquimea.
Master’s Degree in Business and Administration by the UCM. IESE’s Advanced Management Program (AMP) and Program for Management Development (PMD) from the University of Navarra. She has been appointed as board member of several Spanish companies during the last 10 years. In Vaxdyn she was appointed as expert advisor from the Mind the Gap Transferencia Tecnológica investment vehicle led by The Botín Foundation.
Board Member of Vaxdyn appointed by Arquimea Group and secretary of the Board in Arquimea Group.
Lawyer with experience in R&D Management, legal and fiscal management of technology based companies.
Currently, Ricardo is the CEO of Bionova Capital. He was previously an International Business Analyst at BIAL. He was also an Investment Manager at Portugal Ventures where he managed 6 portfolio Biotech companies and scouted for new deals.
He holds a B.Sc. in Biochemistry and a Ph.D. in Molecular Biology, both approved with the Highest Honors. Ricardo is a Harvard and MIT-educated scientist with experience in Venture Capital, Drug Development, Licensing, Business Development and Market Analysis. He performed his PhD work at the Harvard Medical School (Prof. Judy Lieberman’s laboratory). He was also a Research Assistant at the Massachusetts Institute of Technology where he developed a proof-of-concept for using micro-bioreactors as a novel tool for high-throughput screening.
CONTACT
Vaxdyn
Supported by CARB-X
Member of ASEBIO, Spanish Industry Association
Member of BEAM Alliance, Biotech companies from Europe innovating in Anti-Microbial resistance research
